

# Nathan P Wiederhold

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3461036/publications.pdf>

Version: 2024-02-01

263  
papers

11,096  
citations

34493

54  
h-index

53065

89  
g-index

273  
all docs

273  
docs citations

273  
times ranked

10329  
citing authors

#	ARTICLE	IF	CITATIONS
1	Species Distribution and Antifungal Susceptibilities of <i>Aspergillus</i> Section <i>Fumigati</i> Isolates in Clinical Samples from the United States. <i>Journal of Clinical Microbiology</i> , 2022, 60, e0028022.	1.8	18
2	Diagnosis from Tissue: Histology and Identification. <i>Journal of Fungi (Basel, Switzerland)</i> , 2022, 8, 505.	1.5	8
3	Invasive candidiasis: investigational drugs in the clinical development pipeline and mechanisms of action. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 795-812.	1.9	23
4	<i>Fusarium abutilonis</i> and <i>F. guadeloupense</i> , two novel species in the <i>Fusarium buharicum</i> clade supported by multilocus molecular phylogenetic analyses. <i>Mycologia</i> , 2022, 114, 682-696.	0.8	4
5	Genomic Diversity across <i>Candida auris</i> Clinical Isolates Shapes Rapid Development of Antifungal Resistance <i>In Vitro</i> and <i>In Vivo</i> . <i>MBio</i> , 2022, 13, .	1.8	18
6	Phylogenomic Analysis of a 55.1-kb 19-Gene Dataset Resolves a Monophyletic <i>Fusarium</i> that Includes the <i>Fusarium solani</i> Species Complex. <i>Phytopathology</i> , 2021, 111, 1064-1079.	1.1	107
7	Isavuconazole as Primary Antifungal Prophylaxis in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-label, Prospective, Phase 2 Study. <i>Clinical Infectious Diseases</i> , 2021, 72, 1755-1763.	2.9	48
8	Case Report: Successful Management of <i>Conidiobolus lamprauges</i> Rhinitis in a Dog. <i>Frontiers in Veterinary Science</i> , 2021, 8, 633695.	0.9	3
9	Review of T-2307, an Investigational Agent That Causes Collapse of Fungal Mitochondrial Membrane Potential. <i>Journal of Fungi (Basel, Switzerland)</i> , 2021, 7, 130.	1.5	16
10	Pulmonary infection secondary to <i>Blastobotrys raffinosifermentans</i> in a cystic fibrosis patient: Review of the literature. <i>Mycoses</i> , 2021, 64, 616-623.	1.8	2
11	Variability of Hydroxy-Itraconazole in Relation to Itraconazole Bloodstream Concentrations. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	1.4	7
12	Evaluation of Sex Differences in Murine Diabetic Ketoacidosis and Neutropenic Models of Invasive Mucormycosis. <i>Journal of Fungi (Basel, Switzerland)</i> , 2021, 7, 313.	1.5	6
13	In vitro activity of olorofim against clinical isolates of the <i>Fusarium oxysporum</i> and <i>Fusarium solani</i> species complexes. <i>Mycoses</i> , 2021, 64, 748-752.	1.8	19
14	Efficacy and Associated Drug Exposures of Isavuconazole and Fluconazole in an Experimental Model of Coccidioidomycosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	1.4	8
15	Ibrexafungerp Demonstrates <i>In Vitro</i> Activity against Fluconazole-Resistant <i>Candida auris</i> and <i>In Vivo</i> Efficacy with Delayed Initiation of Therapy in an Experimental Model of Invasive Candidiasis. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	1.4	27
16	<i>Pseudocanariomyces americanus</i> , gen. nov., sp. nov., A New Thielavia-Like Species in the Chaetomiaceae: Identification and Management of a Prosthetic Hip Infection. <i>Mycopathologia</i> , 2021, 186, 441-447.	1.3	4
17	First Reported Case of Invasive Cutaneous <i>Penicillium cluniae</i> Infection in a Patient With Acute Myelogenous Leukemia: A Case Report and Literature Review. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab265.	0.4	5
18	Manogepix, the Active Moiety of the Investigational Agent Fosmanogepix, Demonstrates <i>In Vitro</i> Activity against Members of the <i>Fusarium oxysporum</i> and <i>Fusarium solani</i> Species Complexes. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	1.4	17

#	ARTICLE	IF	CITATIONS
19	First report of human infection caused by <i>Colletotrichum chlorophyti</i> occurring in a post-corneal transplant patient with endophthalmitis. <i>Medical Mycology Case Reports</i> , 2021, 32, 73-76.	0.7	6
20	Retrospective study of phaeohyphomycosis in aquarium-housed fish, with first descriptions of <i>Exophiala lecanii</i> and <i>Neodevriesia cladophorae</i> in fish. <i>Journal of Fish Diseases</i> , 2021, 44, 1563-1577.	0.9	5
21	Disseminated <i>Rasamsonia argillacea</i> species complex infections in 8 dogs. <i>Journal of Veterinary Internal Medicine</i> , 2021, 35, 2232-2240.	0.6	8
22	Global guideline for the diagnosis and management of rare yeast infections: an initiative of the ECMM in cooperation with ISHAM and ASM. <i>Lancet Infectious Diseases</i> , The, 2021, 21, e375-e386.	4.6	80
23	Epidemiology and Antifungal Susceptibilities of Mucoralean Fungi in Clinical Samples from the United States. <i>Journal of Clinical Microbiology</i> , 2021, 59, e0123021.	1.8	32
24	A revision of malbranchea-like fungi from clinical specimens in the United States of America reveals unexpected novelty. <i>IMA Fungus</i> , 2021, 12, 25.	1.7	8
25	Antifungal Susceptibility Testing: A Primer for Clinicians. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab444.	0.4	26
26	Emerging Fungal Infections: New Species, New Names, and Antifungal Resistance. <i>Clinical Chemistry</i> , 2021, 68, 83-90.	1.5	28
27	The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin. <i>Drugs</i> , 2021, 81, 1703-1729.	4.9	168
28	Answer to December 2021 Photo Quiz. <i>Journal of Clinical Microbiology</i> , 2021, 59, e0289920.	1.8	0
29	Polymeric Iron Chelator with Enhanced Iron Affinity as a Broad-Spectrum Antifungal Agent. <i>ACS Applied Polymer Materials</i> , 2021, 3, 6034-6039.	2.0	2
30	Photo Quiz: You Get What You Get, and Sometimes It's Tuberculate. <i>Journal of Clinical Microbiology</i> , 2021, 59, e0289720.	1.8	0
31	Fosmanogepix (APX001) Is Effective in the Treatment of Immunocompromised Mice Infected with Invasive Pulmonary Scedosporiosis or Disseminated Fusariosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	55
32	Nanopore Sequencing of the Fungal Intergenic Spacer Sequence as a Potential Rapid Diagnostic Assay. <i>Journal of Clinical Microbiology</i> , 2020, 58, .	1.8	21
33	Genomic characterization of <i>Parengyodontium americanum</i> sp. nov. <i>Fungal Genetics and Biology</i> , 2020, 138, 103351.	0.9	4
34	Review of the Novel Investigational Antifungal Olorofim. <i>Journal of Fungi (Basel, Switzerland)</i> , 2020, 6, 122.	1.5	72
35	<i>Spiromastigoides asexualis</i> : Phylogenetic Analysis and Evaluation as a Cause of False-Positive <i>Blastomyces</i> DNA Probe Test Results. <i>Journal of Clinical Microbiology</i> , 2020, 58, .	1.8	1
36	No to <i>Neocosmospora</i> : Phylogenomic and Practical Reasons for Continued Inclusion of the <i>Fusarium solani</i> Species Complex in the Genus <i>Fusarium</i> . <i>MSphere</i> , 2020, 5, .	1.3	61

#	ARTICLE	IF	CITATIONS
37	Differential Thermotolerance Adaptation between Species of Coccidioides. Journal of Fungi (Basel), Tj ETQq1 1 0.784314 rgBTJ/Overlock	1.5	13
38	The Novel Arylamidine T-2307 Demonstrates <i>In Vitro</i> and <i>In Vivo</i> Activity against <i>Candida auris</i> . Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	34
39	Implications of Evolving and Emerging Pharmacokinetic-Pharmacodynamic Research for Triazoles and Echinocandins. Current Fungal Infection Reports, 2020, 14, 258-267.	0.9	1
40	Fosmanogepix (APX001) Is Effective in the Treatment of Pulmonary Murine Mucormycosis Due to <i>Rhizopus arrhizus</i> . Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	54
41	A Novel <i>Exophiala</i> Species Associated With Disseminated Granulomatous Inflammation in a Captive Eastern Hellbender ( <i>Cryptobranchus alleganiensis alleganiensis</i> ). Frontiers in Veterinary Science, 2020, 7, 25.	0.9	3
42	<i>Aspergillus fumigatus</i> and pan-azole resistance: who should be concerned?. Current Opinion in Infectious Diseases, 2020, 33, 290-297.	1.3	54
43	The genome of opportunistic fungal pathogen <i>Fusarium oxysporum</i> carries a unique set of lineage-specific chromosomes. Communications Biology, 2020, 3, 50.	2.0	55
44	Novel <i>Penicillium</i> species causing disseminated disease in a Labrador Retriever dog. Medical Mycology, 2020, 58, 1053-1063.	0.3	10
45	Rapid and Low-Cost Culture-Based Method for Diagnosis of Mucormycosis Using a Mouse Model. Frontiers in Microbiology, 2020, 11, 440.	1.5	6
46	Three new <i>Curvularia</i> species from clinical and environmental sources. MycoKeys, 2020, 68, 1-21.	0.8	4
47	Trichosporonosis Presenting as an Exophytic Cutaneous Mass Lesion. Mycopathologia, 2020, 185, 705-708.	1.3	2
48	<i>Blastomyces helicus</i> , a New Dimorphic Fungus Causing Fatal Pulmonary and Systemic Disease in Humans and Animals in Western Canada and the United States. Clinical Infectious Diseases, 2019, 68, 188-195.	2.9	68
49	Extended-Interval Dosing of Rezafungin against Azole-Resistant <i>Aspergillus fumigatus</i> . Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	18
50	Impact of the Major <i>Candida glabrata</i> Triazole Resistance Determinants on the Activity of the Novel Investigational Tetrazoles VT-1598 and VT-1161. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	16
51	Antifungal Resistance Testing and Implications for Management. Current Fungal Infection Reports, 2019, 13, 274-283.	0.9	13
52	Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infectious Diseases, The, 2019, 19, e405-e421.	4.6	970
53	Two new species of <i>Gloniopsis</i> (Hysteriales, Ascomycota) from clinical specimens: Morphological and molecular characterisation. Mycoses, 2019, 62, 1164-1173.	1.8	4
54	Efficacy of Delayed Therapy with Fosmanogepix (APX001) in a Murine Model of <i>Candida auris</i> Invasive Candidiasis. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	50

#	ARTICLE	IF	CITATIONS
55	Development of High-Level Echinocandin Resistance in a Patient With Recurrent <i>Candida auris</i> Candidemia Secondary to Chronic Candiduria. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz262.	0.4	71
56	<i>Rasamsonia</i> sp: An emerging infection amongst chronic granulomatous disease patients. A case of disseminated infection by a putatively novel <i>Rasamsonia argillacea</i> species complex involving the heart. <i>Medical Mycology Case Reports</i> , 2019, 24, 54-57.	0.7	13
57	Gastrointestinal pythiosis with concurrent presumptive gastrointestinal basidiobolomycosis in a Boxer dog. <i>Veterinary Clinical Pathology</i> , 2019, 48, 83-88.	0.3	6
58	<i>In Vitro</i> Activities of the Novel Investigational Tetrazoles VT-1161 and VT-1598 Compared to the Triazole Antifungals against Azole-Resistant Strains and Clinical Isolates of <i>Candida albicans</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	29
59	Mutations in <i>hmg1</i> , Challenging the Paradigm of Clinical Triazole Resistance in <i>Aspergillus fumigatus</i> . <i>MBio</i> , 2019, 10, .	1.8	85
60	Shielding the Next Generation: Symbiotic Bacteria from a Reproductive Organ Protect Bobtail Squid Eggs from Fungal Fouling. <i>MBio</i> , 2019, 10, .	1.8	30
61	<i>In Vitro</i> Activity of Essential Oils Against Gram-Positive and Gram-Negative Clinical Isolates, Including Carbapenem-Resistant Enterobacteriaceae. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz502.	0.4	22
62	Examination of Fluconazole-Induced Alopecia in an Animal Model and Human Cohort. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	6
63	Novel <i>Paranannizziopsis</i> species in a Wagler's viper ( <i>Tropidolaemus wagleri</i> ), tentacled snakes ( <i>Erpeton tentaculatum</i> ), and a rhinoceros snake ( <i>Rhynchophis boulengeri</i> ) in a zoological collection. <i>Medical Mycology</i> , 2019, 57, 825-832.	0.3	10
64	The Fungal Cyp51-Specific Inhibitor VT-1598 Demonstrates <i>In Vitro</i> and <i>In Vivo</i> Activity against <i>Candida auris</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	53
65	Oral glucan synthase inhibitor SCY-078 is effective in an experimental murine model of invasive candidiasis caused by WT and echinocandin-resistant <i>Candida glabrata</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 448-451.	1.3	40
66	Reduced Antifungal Susceptibility of Vulvovaginal <i>Candida</i> Species at Normal Vaginal pH Levels: Clinical Implications. <i>Journal of Lower Genital Tract Disease</i> , 2018, 22, 152-158.	0.9	26
67	The Black Yeasts: an Update on Species Identification and Diagnosis. <i>Current Fungal Infection Reports</i> , 2018, 12, 59-65.	0.9	14
68	The Novel Fungal Cyp51 Inhibitor VT-1598 Is Efficacious in Experimental Models of Central Nervous System Coccidioidomycosis Caused by <i>Coccidioides posadasii</i> and <i>Coccidioides immitis</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	32
69	Fungal-specific Cyp51 inhibitor VT-1598 demonstrates <i>in vitro</i> activity against <i>Candida</i> and <i>Cryptococcus</i> species, endemic fungi, including <i>Coccidioides</i> species, <i>Aspergillus</i> species and <i>Rhizopus arrhizus</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 404-408.	1.3	49
70	Antifungal Susceptibility and Clinical Outcome in Neonatal Candidiasis. <i>Pediatric Infectious Disease Journal</i> , 2018, 37, 923-929.	1.1	16
71	Multi-locus sequence typing provides epidemiological insights for diseased sharks infected with fungi belonging to the <i>Fusarium solani</i> species complex. <i>Medical Mycology</i> , 2018, 56, 591-601.	0.3	11
72	Species of <i>Aspergillus</i> section <i>Aspergillus</i> from clinical samples in the United States. <i>Medical Mycology</i> , 2018, 56, 541-550.	0.3	17

#	ARTICLE	IF	CITATIONS
73	Fungal infections in animals: a patchwork of different situations. <i>Medical Mycology</i> , 2018, 56, S165-S187.	0.3	141
74	Dynamics of Mixed <i>Candida</i> Species Biofilms in Response to Antifungals. <i>Journal of Dental Research</i> , 2018, 97, 91-98.	2.5	30
75	The antifungal arsenal: alternative drugs and future targets. <i>International Journal of Antimicrobial Agents</i> , 2018, 51, 333-339.	1.1	110
76	Coelomycetous <i>Dothideomycetes</i> with emphasis on the families <i>Cucurbitariaceae</i> and <i>Didymellaceae</i> . <i>Studies in Mycology</i> , 2018, 90, 1-69.	4.5	129
77	Multicenter Evaluation of the Vitek MS v3.0 System for the Identification of Filamentous Fungi. <i>Journal of Clinical Microbiology</i> , 2018, 56, .	1.8	73
78	Lung Abscess Due to <i>Aspergillus lentulus</i> and <i>Pseudomonas aeruginosa</i> in a Patient With Granulomatosis With Polyangiitis. <i>Infectious Diseases in Clinical Practice</i> , 2018, 26, 100-105.	0.1	2
79	2393. Evaluation of Antifungal Treatment in a Neutropenic Mouse Model of Scedosporiosis. <i>Open Forum Infectious Diseases</i> , 2018, 5, S713-S714.	0.4	0
80	From the Clinical Mycology Laboratory: New Species and Changes in Fungal Taxonomy and Nomenclature. <i>Journal of Fungi (Basel, Switzerland)</i> , 2018, 4, 138.	1.5	13
81	Advanced Molecular Diagnosis of Fungal Infections. , 2018, , 403-421.		0
82	Molecular diagnostics in medical mycology. <i>Nature Communications</i> , 2018, 9, 5135.	5.8	103
83	Cryptic <i>Aspergillus</i> from clinical samples in the USA and description of a new species in section <i>Flavipedes</i> . <i>Mycoses</i> , 2018, 61, 814-825.	1.8	16
84	The Orotomide Olorofim Is Efficacious in an Experimental Model of Central Nervous System Coccidioidomycosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	46
85	Antifungal Use in Veterinary Practice and Emergence of Resistance. , 2018, , 359-402.		6
86	Invasive Rhinosinusitis Caused by <i>Lasiodiplodia theobromae</i> in an Allogeneic Hematopoietic Cell Transplant Recipient Case Report and Review of Literature. <i>Mycopathologia</i> , 2018, 183, 841-845.	1.3	1
87	<i>In Vitro</i> Activity of Isavuconazole against Opportunistic Fungal Pathogens from Two Mycology Reference Laboratories. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	43
88	Rezafungin (CD101) demonstrates potent in vitro activity against <i>Aspergillus</i> , including azole-resistant <i>Aspergillus fumigatus</i> isolates and cryptic species. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 3063-3067.	1.3	59
89	<i>Emergomyces canadensis</i> , a Dimorphic Fungus Causing Fatal Systemic Human Disease in North America. <i>Emerging Infectious Diseases</i> , 2018, 24, 758-761.	2.0	46
90	The Fungal Cyp51 Inhibitor VT-1129 Is Efficacious in an Experimental Model of Cryptococcal Meningitis. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	23

#	ARTICLE	IF	CITATIONS
91	Screening a Repurposing Library for Inhibitors of Multidrug-Resistant <i>Candida auris</i> Identifies Ebselen as a Repositionable Candidate for Antifungal Drug Development. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	68
92	In Vivo Efficacy of VT-1129 against Experimental Cryptococcal Meningitis with the Use of a Loading Dose-Maintenance Dose Administration Strategy. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	23
93	Repurposing auranofin as an antifungal: <i>in vitro</i> activity against a variety of medically important fungi. <i>Virulence</i> , 2017, 8, 138-142.	1.8	75
94	Large-Scale Evaluation of <i>In Vitro</i> Amphotericin B, Triazole, and Echinocandin Activity against <i>Coccidioides</i> Species from U.S. Institutions. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	42
95	Multilocus Phylogeny and Antifungal Susceptibility of <i>Aspergillus</i> Section <i>Circumdati</i> from Clinical Samples and Description of <i>A. pseudosclerotiorum</i> sp. nov. <i>Journal of Clinical Microbiology</i> , 2017, 55, 947-958.	1.8	18
96	Prophylaxis with Isavuconazole or Posaconazole Protects Immunosuppressed Mice from Pulmonary Mucormycosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	17
97	Fatal disseminated <i>Rasamsonia</i> infection in cystic fibrosis post-lung transplantation. <i>Journal of Cystic Fibrosis</i> , 2017, 16, e3-e7.	0.3	28
98	New <i>acremonium</i> -like species in the <i>Bionectriaceae</i> and <i>Plectosphaerellaceae</i> . <i>Mycological Progress</i> , 2017, 16, 349-368.	0.5	16
99	The Tetrazole VT-1161 Is a Potent Inhibitor of <i>Trichophyton rubrum</i> through Its Inhibition of <i>T. rubrum</i> CYP51. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	20
100	Loss of C-5 Sterol Desaturase Activity Results in Increased Resistance to Azole and Echinocandin Antifungals in a Clinical Isolate of <i>Candida parapsilosis</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	42
101	Dihydroorotate dehydrogenase inhibitor F901318 has potent <i>in vitro</i> activity against <i>Scedosporium</i> species and <i>Lomentospora prolificans</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 1977-1980.	1.3	72
102	Fungal Keratitis Secondary to <i>Trametes betulina</i> : A Case Report and Review of Literature. <i>Mycopathologia</i> , 2017, 182, 755-759.	1.3	7
103	Coelomycetous Fungi in the Clinical Setting: Morphological Convergence and Cryptic Diversity. <i>Journal of Clinical Microbiology</i> , 2017, 55, 552-567.	1.8	54
104	Culture-Independent Molecular Methods for Detection of Antifungal Resistance Mechanisms and Fungal Identification. <i>Journal of Infectious Diseases</i> , 2017, 216, S458-S465.	1.9	40
105	PHARMACOKINETICS OF ORALLY ADMINISTERED VORICONAZOLE IN AFRICAN PENGUINS ( <i>SPHENISCUS</i> ) <i>Tj ETQq1 1 0.784314 rgBT</i> 352-362.	0.3	15
106	New Species <i>Spiromastigoides albida</i> from a Lung Biopsy. <i>Mycopathologia</i> , 2017, 182, 967-978.	1.3	6
107	Multiple Brain Abscesses Caused by <i>Trichosporon inkin</i> in a Patient with X-Linked Chronic Granulomatous Disease (CGD) Successfully Treated with Antifungal Therapy. <i>Journal of Clinical Immunology</i> , 2017, 37, 519-523.	2.0	5
108	Update on Therapeutic Drug Monitoring of Antifungals for the Prophylaxis and Treatment of Invasive Fungal Infections. <i>Current Fungal Infection Reports</i> , 2017, 11, 75-83.	0.9	4

#	ARTICLE	IF	CITATIONS
109	Prophylactic Treatment with VT-1161 Protects Immunosuppressed Mice from <i>Rhizopus arrhizus</i> var. <i>arrhizus</i> Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	31
110	Four new species of <i>Talaromyces</i> from clinical sources. <i>Mycoses</i> , 2017, 60, 651-662.	1.8	27
111	Monotherapy or combination therapy of isavuconazole and micafungin for treating murine mucormycosis. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 462-466.	1.3	37
112	Modified release itraconazole amorphous solid dispersion to treat <i>Aspergillus fumigatus</i> : importance of the animal model selection. <i>Drug Development and Industrial Pharmacy</i> , 2017, 43, 264-274.	0.9	6
113	In vitro Susceptibility Testing of Essential Oils against Gram-positive and Gram-negative Clinical Isolates, including Carbapenem-resistant Enterobacteriaceae (CRE). <i>Open Forum Infectious Diseases</i> , 2017, 4, S370-S370.	0.4	1
114	APX001A Protects Immunosuppressed Mice from <i>Rhizopus delemar</i> Infection. <i>Open Forum Infectious Diseases</i> , 2017, 4, S475-S475.	0.4	10
115	In vitro Activity of Fosfomycin, Alone and Combined with Cefepime and Meropenem, Against Carbapenemase-Producing Gram-Negative Bacteria. <i>Open Forum Infectious Diseases</i> , 2017, 4, S374-S374.	0.4	1
116	Antifungal resistance: current trends and future strategies to combat. <i>Infection and Drug Resistance</i> , 2017, Volume 10, 249-259.	1.1	305
117	Fungal Planet description sheets: 558-624. <i>Persoonia: Molecular Phylogeny and Evolution of Fungi</i> , 2017, 38, 240-384.	1.6	126
118	<i>Blastomyces helicus</i> , an Emerging Dimorphic Fungal Pathogen Causing Fatal Pulmonary and Disseminated Disease in Humans and Animals in Western Canada and United States. <i>Open Forum Infectious Diseases</i> , 2017, 4, S83-S84.	0.4	4
119	Diversity of <i>Veronaea botryosa</i> from different hosts and evaluation of laboratory challenge models for phaeohyphomycosis in <i>Acipenser transmontanus</i> . <i>Diseases of Aquatic Organisms</i> , 2017, 125, 7-18.	0.5	14
120	Fungal Drug Resistance: Azoles. , 2017, , 397-405.		1
121	Pharmacokinetics and safety of posaconazole delayed-release tablets for invasive fungal infections. <i>Clinical Pharmacology: Advances and Applications</i> , 2016, 8, 1.	0.8	24
122	New species of <i>Cladosporium</i> ; associated with human and animal infections. <i>Persoonia: Molecular Phylogeny and Evolution of Fungi</i> , 2016, 36, 281-298.	1.6	95
123	Invasive <i>Microsporium canis</i> causing rhinitis and stomatitis in a cat. <i>Journal of Small Animal Practice</i> , 2016, 57, 327-331.	0.5	3
124	Yeasts. <i>Microbiology Spectrum</i> , 2016, 4, .	1.2	0
125	Fungal Planet description sheets: 469-557. <i>Persoonia: Molecular Phylogeny and Evolution of Fungi</i> , 2016, 37, 218-403.	1.6	196
126	Comparison of Nonculture Blood-Based Tests for Diagnosing Invasive Aspergillosis in an Animal Model. <i>Journal of Clinical Microbiology</i> , 2016, 54, 960-966.	1.8	19



#	ARTICLE	IF	CITATIONS
127	Effect of Antifungal Treatment in a Diet-Based Murine Model of Disseminated Candidiasis Acquired via the Gastrointestinal Tract. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 6703-6708.	1.4	15
128	Fungal Planet description sheets: 400–468. <i>Persoonia: Molecular Phylogeny and Evolution of Fungi</i> , 2016, 36, 316-458.	1.6	193
129	Veterinary Fusarioses within the United States. <i>Journal of Clinical Microbiology</i> , 2016, 54, 2813-2819.	1.8	41
130	The Celecoxib Derivative AR-12 Has Broad-Spectrum Antifungal Activity <i>In Vitro</i> and Improves the Activity of Fluconazole in a Murine Model of Cryptococcosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 7115-7127.	1.4	69
131	Phylogeny and taxonomic revision of <i>Microascaceae</i> with emphasis on synnematosous fungi. <i>Studies in Mycology</i> , 2016, 83, 193-233.	4.5	44
132	Efficacy of echinocandins against murine infections by <i>Candida rugosa</i> . <i>Diagnostic Microbiology and Infectious Disease</i> , 2016, 86, 61-65.	0.8	3
133	<i>Schizophyllum radiatum</i> , an Emerging Fungus from Human Respiratory Tract. <i>Journal of Clinical Microbiology</i> , 2016, 54, 2491-2497.	1.8	11
134	Species diversity of <i>Aspergillus</i> section <i>Versicolores</i> in clinical samples and antifungal susceptibility. <i>Fungal Biology</i> , 2016, 120, 1458-1467.	1.1	27
135	Echinocandin Resistance in <i>Candida</i> Species: a Review of Recent Developments. <i>Current Infectious Disease Reports</i> , 2016, 18, 42.	1.3	30
136	F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 12809-12814.	3.3	187
137	Isavuconazole Is Effective for the Treatment of Experimental Cryptococcal Meningitis. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 5600-5603.	1.4	36
138	<i>Schwanniomyces etchellsii</i> : an unusual cause of fungemia in a patient with cholecystitis. <i>Diagnostic Microbiology and Infectious Disease</i> , 2016, 84, 221-222.	0.8	3
139	Identification and Antifungal Susceptibility of <i>Penicillium</i> -Like Fungi from Clinical Samples in the United States. <i>Journal of Clinical Microbiology</i> , 2016, 54, 2155-2161.	1.8	47
140	The Investigational Fungal Cyp51 Inhibitor VT-1129 Demonstrates Potent <i>In Vitro</i> Activity against <i>Cryptococcus neoformans</i> and <i>Cryptococcus gattii</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 2528-2531.	1.4	58
141	International Evaluation of MIC Distributions and Epidemiological Cutoff Value (ECV) Definitions for <i>Fusarium</i> Species Identified by Molecular Methods for the CLSI Broth Microdilution Method. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 1079-1084.	1.4	113
142	The novel arylamidine T-2307 demonstrates <i>in vitro</i> and <i>in vivo</i> activity against echinocandin-resistant <i>Candida glabrata</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 692-695.	1.3	33
143	What's Old is New: Recognition of New Fungal Pathogens in the Era of Phylogenetics and Changing Taxonomy and Implications for Medical Mycology. <i>Fungal Biology</i> , 2016, , 451-467.	0.3	0
144	Effects of Treated versus Untreated Polystyrene on Caspofungin <i>In Vitro</i> Activity against <i>Candida</i> Species. <i>Journal of Clinical Microbiology</i> , 2016, 54, 734-738.	1.8	11

#	ARTICLE	IF	CITATIONS
145	Voriconazole minimum inhibitory concentrations are predictive of treatment outcome in experimental murine infections by <i>Candida glabrata</i> . <i>International Journal of Antimicrobial Agents</i> , 2016, 47, 286-288.	1.1	4
146	<i>Ustilago echinata</i> : Infection in a Mixed Martial Artist Following an Open Fracture. <i>Mycopathologia</i> , 2016, 181, 311-314.	1.3	2
147	Development of a <i>Candida glabrata</i> dominant nutritional transformation marker utilizing the <i>Aspergillus nidulans</i> acetamidase gene ( <i>amdS</i> ). <i>FEMS Yeast Research</i> , 2016, 16, fow023.	1.1	4
148	Update from the Laboratory. <i>Infectious Disease Clinics of North America</i> , 2016, 30, 13-35.	1.9	26
149	Multilaboratory Evaluation of <i>In Vitro</i> Antifungal Susceptibility Testing of Dermatophytes for ME1111. <i>Journal of Clinical Microbiology</i> , 2016, 54, 662-665.	1.8	7
150	First Detection of TR34 L98H and TR46 Y121F T289A Cyp51 Mutations in <i>Aspergillus fumigatus</i> Isolates in the United States. <i>Journal of Clinical Microbiology</i> , 2016, 54, 168-171.	1.8	143
151	Voriconazole and posaconazole therapy for experimental <i>Candida lusitanae</i> infection. <i>Diagnostic Microbiology and Infectious Disease</i> , 2016, 84, 48-51.	0.8	6
152	What's new in antifungals. <i>Current Opinion in Infectious Diseases</i> , 2015, 28, 539-545.	1.3	16
153	A Case of Phaeohyphomycosis Caused by <i>Exophiala oligosperma</i> in a Renal Transplant Patient Successfully Treated with Posaconazole. <i>American Journal of Infectious Diseases</i> , 2015, 11, 15-19.	0.1	1
154	Fungal arthritis secondary to <i>Colletotrichum gloeosporioides</i> . <i>JMM Case Reports</i> , 2015, 2, .	1.3	4
155	Combat-Related <i>Pythium aphanidermatum</i> Invasive Wound Infection: Case Report and Discussion of Utility of Molecular Diagnostics. <i>Journal of Clinical Microbiology</i> , 2015, 53, 1968-1975.	1.8	35
156	Identification of a New Class of Antifungals Targeting the Synthesis of Fungal Sphingolipids. <i>MBio</i> , 2015, 6, e00647.	1.8	124
157	Detection of triazole resistance among <i>Candida</i> species by matrix-assisted laser desorption/ionization-time of flight mass spectrometry (MALDI-TOF MS). <i>Medical Mycology</i> , 2015, 53, 736-742.	0.3	46
158	<i>Cladosporium</i> Species Recovered from Clinical Samples in the United States. <i>Journal of Clinical Microbiology</i> , 2015, 53, 2990-3000.	1.8	109
159	<i>Acrophialophora</i> , a Poorly Known Fungus with Clinical Significance. <i>Journal of Clinical Microbiology</i> , 2015, 53, 1549-1555.	1.8	16
160	Pulmonary Fungal Infection Caused by <i>Neoscytalidium dimidiatum</i> . <i>Journal of Clinical Microbiology</i> , 2015, 53, 2381-2384.	1.8	22
161	Efficacy of the Investigational Echinocandin ASP9726 in a Guinea Pig Model of Invasive Pulmonary Aspergillosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 2875-2881.	1.4	20
162	Evaluation of VT-1161 for Treatment of Coccidioidomycosis in Murine Infection Models. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 7249-7254.	1.4	46

#	ARTICLE	IF	CITATIONS
163	VT-1161 Protects Immunosuppressed Mice from <i>Rhizopus arrhizus</i> var. <i>arrhizus</i> Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 7815-7817.	1.4	44
164	Emergence of Azole Resistance in <i>Aspergillus</i> . <i>Seminars in Respiratory and Critical Care Medicine</i> , 2015, 36, 673-680.	0.8	45
165	Morphological and Molecular Characterization of <i>Exophiala polymorpha</i> sp. nov. Isolated from Sporotrichoid Lymphocutaneous Lesions in a Patient with Myasthenia Gravis. <i>Journal of Clinical Microbiology</i> , 2015, 53, 2816-2822.	1.8	17
166	First Human Case of Fungal Keratitis Caused by a Putatively Novel Species of <i>Lophotrichus</i> . <i>Journal of Clinical Microbiology</i> , 2015, 53, 3063-3067.	1.8	8
167	Disseminated <i>Conidiobolus incongruus</i> in a dog: A case report and literature review. <i>Medical Mycology Case Reports</i> , 2015, 8, 24-28.	0.7	6
168	The Investigational Agent E1210 Is Effective in Treatment of Experimental Invasive Candidiasis Caused by Resistant <i>Candida albicans</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 690-692.	1.4	51
169	The Novel Arylamidine T-2307 Maintains <i>In Vitro</i> and <i>In Vivo</i> Activity against Echinocandin-Resistant <i>Candida albicans</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 1341-1343.	1.4	29
170	Phaeohyphomycosis resulting in obstructive tracheitis in three green sea turtles <i>Chelonia mydas</i> stranded along the Florida coast. <i>Diseases of Aquatic Organisms</i> , 2015, 113, 257-262.	0.5	21
171	Probable case of <i>Cephalotheca foveolata</i> bloodstream infection. <i>JMM Case Reports</i> , 2015, 2, .	1.3	0
172	Occurrence of <i>Ochroconis</i> and <i>Verruconis</i> Species in Clinical Specimens from the United States. <i>Journal of Clinical Microbiology</i> , 2014, 52, 4189-4201.	1.8	50
173	<i>Pithomyces</i> species (Montagnulaceae) from clinical specimens: identification and antifungal susceptibility profiles. <i>Medical Mycology</i> , 2014, 52, 748-757.	0.3	21
174	Isolation and characterisation of the fungus <i>Spiromastix asexualis</i> sp. nov. from discospondylitis in a German Shepherd dog, and review of <i>Spiromastix</i> with the proposal of the new order <i>Spiromastixales</i> (Ascomycota). <i>Mycoses</i> , 2014, 57, 419-428.	1.8	15
175	Luliconazole Demonstrates Potent <i>In Vitro</i> Activity against Dermatophytes Recovered from Patients with Onychomycosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 3553-3555.	1.4	32
176	First Report of <i>Westerdykella dispersa</i> as a Cause of an Angioinvasive Fungal Infection in a Neutropenic Host. <i>Journal of Clinical Microbiology</i> , 2014, 52, 4407-4411.	1.8	7
177	Phylogeny of the Clinically Relevant Species of the Emerging Fungus <i>Trichoderma</i> and Their Antifungal Susceptibilities. <i>Journal of Clinical Microbiology</i> , 2014, 52, 2112-2125.	1.8	71
178	Impact of New Antifungal Breakpoints on Antifungal Resistance in <i>Candida</i> Species. <i>Journal of Clinical Microbiology</i> , 2014, 52, 994-997.	1.8	73
179	<i>Spiromastix tachybotrys eucylindrospora</i> isolated from foreign material following a traumatic eye injury. <i>Mycoses</i> , 2014, 57, 437-441.	1.8	1
180	Disruption of the Transcriptional Regulator Cas5 Results in Enhanced Killing of <i>Candida albicans</i> by Fluconazole. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 6807-6818.	1.4	45

#	ARTICLE	IF	CITATIONS
181	Paradoxical antifungal activity and structural observations in biofilms formed by echinocandin-resistant <i>Candida albicans</i> clinical isolates. <i>Medical Mycology</i> , 2014, 52, 131-139.	0.3	20
182	Multifocal <i>Rhizopus microsporus</i> lung infection following brush clearing. <i>Medical Mycology Case Reports</i> , 2014, 6, 14-17.	0.7	12
183	A Reference Laboratory Experience of Clinically Achievable Voriconazole, Posaconazole, and Itraconazole Concentrations within the Bloodstream and Cerebral Spinal Fluid. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 424-431.	1.4	61
184	Paravertebral Mushroom: Identification of a Novel Species of <i>Phellinus</i> as a Human Pathogen in Chronic Granulomatous Disease. <i>Journal of Clinical Microbiology</i> , 2014, 52, 2726-2729.	1.8	10
185	Clinical, Morphological, and Molecular Characterization of <i>Penicillium canis</i> sp. nov., Isolated from a Dog with Osteomyelitis. <i>Journal of Clinical Microbiology</i> , 2014, 52, 2447-2453.	1.8	18
186	Influence of Serum and Albumin on Echinocandin In Vitro Potency and Pharmacodynamics. <i>Current Fungal Infection Reports</i> , 2013, 7, 89-95.	0.9	8
187	Animal Models In Mycology: What Have We Learned Over The Past 30 Years. <i>Current Fungal Infection Reports</i> , 2013, 7, 68-78.	0.9	9
188	Rapid Emergence of Echinocandin Resistance in <i>Candida glabrata</i> Resulting in Clinical and Microbiologic Failure. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 4559-4561.	1.4	92
189	Limited Activity of Miltefosine in Murine Models of Cryptococcal Meningoencephalitis and Disseminated Cryptococcosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 745-750.	1.4	33
190	Microbiology and epidemiology of oral yeast colonization in hemopoietic progenitor cell transplant recipients. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2013, 115, 354-358.	0.2	15
191	A case of <i>Exophiala oligosperma</i> successfully treated with voriconazole. <i>Medical Mycology Case Reports</i> , 2013, 2, 144-147.	0.7	20
192	Efficacy of Liposomal Amphotericin B and Posaconazole in Intratracheal Models of Murine Mucormycosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 3340-3347.	1.4	54
193	Interlaboratory and Interstudy Reproducibility of a Novel Lateral-Flow Device and Influence of Antifungal Therapy on Detection of Invasive Pulmonary Aspergillosis. <i>Journal of Clinical Microbiology</i> , 2013, 51, 459-465.	1.8	54
194	Comparison of MICs of Fluconazole and Flucytosine When Dissolved in Dimethyl Sulfoxide or Water. <i>Journal of Clinical Microbiology</i> , 2013, 51, 1955-1957.	1.8	6
195	Reply to "Interlaboratory and Interstudy Reproducibility of a Novel Lateral-Flow Device: a Statistical Issue". <i>Journal of Clinical Microbiology</i> , 2013, 51, 1653-1653.	1.8	1
196	Prolyl endopeptidase activity in bronchoalveolar lavage fluid: a novel diagnostic biomarker in a guinea pig model of invasive pulmonary aspergillosis. <i>Medical Mycology</i> , 2013, 51, 592-602.	0.3	5
197	Invasive Fungal Infection Due to <i>Triadelpia pulvinata</i> in a Patient with Acute Myeloid Leukemia. <i>Journal of Clinical Microbiology</i> , 2013, 51, 3426-3429.	1.8	10
198	Assessment of <i>Aspergillus fumigatus</i> in Guinea Pig Bronchoalveolar Lavages and Pulmonary Tissue by Culture and Realtime Polymerase Chain Reaction Studies. <i>International Journal of Molecular Sciences</i> , 2012, 13, 726-736.	1.8	2

#	ARTICLE	IF	CITATIONS
199	A murine model of <i>Cryptococcus gattii</i> meningoencephalitis. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 1432-1438.	1.3	25
200	Detection and Measurement of Fungal Burden in a Guinea Pig Model of Invasive Pulmonary Aspergillosis by Novel Quantitative Nested Real-Time PCR Compared with Galactomannan and (1,3)- $\beta$ -D-Glucan Detection. <i>Journal of Clinical Microbiology</i> , 2012, 50, 602-608.	1.8	28
201	The Changing Epidemiology of Oropharyngeal Candidiasis in Patients with HIV/AIDS in the Era of Antiretroviral Therapy. <i>AIDS Research and Treatment</i> , 2012, 2012, 1-5.	0.3	67
202	Caspofungin for the Treatment of Immunocompromised and Severely Ill Children and Neonates with Invasive Fungal Infections. <i>Clinical Medicine Insights Pediatrics</i> , 2012, 6, CMPed.S8016.	0.7	2
203	Prophylactic efficacy of single dose pulmonary administration of amphotericin B inhalation powder in a guinea pig model of invasive pulmonary aspergillosis. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 970-976.	1.3	20
204	Dry powder insufflation of crystalline and amorphous voriconazole formulations produced by thin film freezing to mice. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2012, 81, 600-608.	2.0	58
205	Antibacterials as Adjuncts to Incision and Drainage for Adults with Purulent Methicillin-Resistant <i>Staphylococcus aureus</i> (MRSA) Skin Infections. <i>Drugs</i> , 2012, 72, 339-351.	4.9	11
206	Comparison of anidulafungin's and fluconazole's in vivo activity in neutropenic and non-neutropenic models of invasive candidiasis. <i>Clinical Microbiology and Infection</i> , 2012, 18, E20-E23.	2.8	21
207	Genomewide Expression Profile Analysis of the <i>Candida glabrata</i> Pdr1 Regulon. <i>Eukaryotic Cell</i> , 2011, 10, 373-383.	3.4	77
208	Caspofungin Dose Escalation for Invasive Candidiasis Due to Resistant <i>Candida albicans</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 3254-3260.	1.4	55
209	Using Antifungal Pharmacodynamics to Improve Patient Outcomes. <i>Current Fungal Infection Reports</i> , 2010, 4, 70-77.	0.9	0
210	Isavuconazole: A Comprehensive Review of Spectrum of Activity of a New Triazole. <i>Mycopathologia</i> , 2010, 170, 291-313.	1.3	118
211	In vitro characterization and pharmacokinetics in mice following pulmonary delivery of itraconazole as cyclodextrin solubilized solution. <i>European Journal of Pharmaceutical Sciences</i> , 2010, 39, 336-347.	1.9	44
212	Efficacy of Posaconazole as Treatment and Prophylaxis against <i>Fusarium solani</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 1055-1059.	1.4	23
213	Loss of <i>in vitro</i> resistance in <i>Candida glabrata</i> following discontinuation of fluconazole prophylaxis in a hematopoietic stem cell transplantation patient. <i>Medical Mycology</i> , 2010, 48, 557-560.	0.3	3
214	Antifungal activity against <i>Scedosporium</i> species and novel assays to assess antifungal pharmacodynamics against filamentous fungi. <i>Medical Mycology</i> , 2009, 47, 422-432.	0.3	34
215	Paradoxical echinocandin activity: a limited <i>in vitro</i> phenomenon?. <i>Medical Mycology</i> , 2009, 47, S369-S375.	0.3	45
216	Inhaled Voriconazole for Prevention of Invasive Pulmonary Aspergillosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 2613-2615.	1.4	41

#	ARTICLE	IF	CITATIONS
217	In vitro activity of isavuconazole against <i>Trichosporon</i> , <i>Rhodotorula</i> , <i>Geotrichum</i> , <i>Saccharomyces</i> and <i>Pichia</i> species. <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 64, 79-83.	1.3	58
218	Antifungal Susceptibilities among Different Serotypes of <i>Cryptococcus gattii</i> and <i>Cryptococcus neoformans</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 309-311.	1.4	114
219	Comparison of Lateral Flow Technology and Galactomannan and (1 $\beta$ -D)-Glucan Assays for Detection of Invasive Pulmonary Aspergillosis. <i>Vaccine Journal</i> , 2009, 16, 1844-1846.	3.2	48
220	Recommended Education for Pharmacists as Competitive Clinical Scientists. <i>Pharmacotherapy</i> , 2009, 29, 236-244.	1.2	33
221	Pharmacology, in vitro activity, and in vivo efficacy of new antifungal agents. <i>Current Fungal Infection Reports</i> , 2009, 3, 77-85.	0.9	2
222	Dose tolerability of chronically inhaled voriconazole solution in rodents. <i>International Journal of Pharmaceutics</i> , 2009, 379, 25-31.	2.6	18
223	Characterization and pharmacokinetic analysis of aerosolized aqueous voriconazole solution. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2009, 72, 199-205.	2.0	50
224	Drug delivery strategies for improved azole antifungal action. <i>Expert Opinion on Drug Delivery</i> , 2008, 5, 1199-1216.	2.4	57
225	Antimicrobial breakpoints for Gram-negative aerobic bacteria based on pharmacokinetic-pharmacodynamic models with Monte Carlo simulation. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 61, 621-628.	1.3	94
226	Increases in <i>SLT2</i> Expression and Chitin Content Are Associated with Incomplete Killing of <i>Candida glabrata</i> by Caspofungin. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 1144-1146.	1.4	62
227	Evaluation of Etest Method for Determining Isavuconazole MICs against <i>Cryptococcus gattii</i> and <i>Cryptococcus neoformans</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 2959-2961.	1.4	30
228	Assessment of Serum (1 $\beta$ -D)-Glucan Concentration as a Measure of Disease Burden in a Murine Model of Invasive Pulmonary Aspergillosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 1176-1178.	1.4	21
229	Development of Caspofungin Resistance following Prolonged Therapy for Invasive Candidiasis Secondary to <i>Candida glabrata</i> Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 3783-3785.	1.4	150
230	Evaluation of aminocandin and caspofungin against <i>Candida glabrata</i> including isolates with reduced caspofungin susceptibility. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 62, 1094-1100.	1.3	26
231	Pyrosequencing To Detect Mutations in <i>FKS1</i> That Confer Reduced Echinocandin Susceptibility in <i>Candida albicans</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 4145-4148.	1.4	49
232	Micafungin in the treatment of invasive candidiasis and invasive aspergillosis. <i>Infection and Drug Resistance</i> , 2008, 1, 63-77.	1.1	10
233	In Vivo Efficacy of Anidulafungin and Caspofungin against <i>Candida glabrata</i> and Association with In Vitro Potency in the Presence of Sera. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 1616-1620.	1.4	74
234	Attenuation of echinocandin activity at elevated concentrations: a review of the paradoxical effect. <i>Current Opinion in Infectious Diseases</i> , 2007, 20, 574-578.	1.3	63

#	ARTICLE	IF	CITATIONS
235	The echinocandin micafungin: a review of the pharmacology, spectrum of activity, clinical efficacy and safety. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 1155-1166.	0.9	53
236	Murine airway histology and intracellular uptake of inhaled amorphous itraconazole. <i>International Journal of Pharmaceutics</i> , 2007, 338, 219-224.	2.6	27
237	Aerosolized nanostructured itraconazole as prophylaxis against invasive pulmonary aspergillosis. <i>Journal of Infection</i> , 2007, 55, 68-74.	1.7	36
238	Pentamidine Is Active in a Neutropenic Murine Model of Acute Invasive Pulmonary Fusariosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 294-297.	1.4	10
239	In vitro pharmacodynamics of rapid versus continuous infusion of amphotericin B deoxycholate against <i>Candida</i> species in the presence of human serum albumin. <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 57, 288-293.	1.3	22
240	Pharmacodynamic Activity of Amphotericin B Deoxycholate Is Associated with Peak Plasma Concentrations in a Neutropenic Murine Model of Invasive Pulmonary Aspergillosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 469-473.	1.4	92
241	In Vivo Efficacy of Aerosolized Nanostructured Itraconazole Formulations for Prevention of Invasive Pulmonary Aspergillosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 1552-1554.	1.4	45
242	Effect of Amphotericin B and Micafungin Combination on Survival, Histopathology, and Fungal Burden in Experimental Aspergillosis in the p47 phox <sup>Δ</sup> / <sup>Δ</sup> Mouse Model of Chronic Granulomatous Disease. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 422-427.	1.4	66
243	In Vitro Pharmacodynamics of Anidulafungin and Caspofungin against <i>Candida glabrata</i> Isolates, Including Strains with Decreased Caspofungin Susceptibility. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 3926-3928.	1.4	41
244	Toll <sup>Δ</sup> Deficient <i>Drosophila</i> Flies as a Fast, High <sup>Δ</sup> Throughput Model for the Study of Antifungal Drug Efficacy against Invasive Aspergillosis and <i>Aspergillus</i> Virulence. <i>Journal of Infectious Diseases</i> , 2005, 191, 1188-1195.	1.9	84
245	Antibacterial activity of linezolid and vancomycin in an in vitro pharmacodynamic model of Gram-positive catheter-related bacteraemia. <i>Journal of Antimicrobial Chemotherapy</i> , 2005, 55, 792-795.	1.3	47
246	Attenuation of the Activity of Caspofungin at High Concentrations against <i>Candida albicans</i> : Possible Role of Cell Wall Integrity and Calcineurin Pathways. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 5146-5148.	1.4	127
247	Frequency and Species Distribution of Gliotoxin-Producing <i>Aspergillus</i> Isolates Recovered from Patients at a Tertiary-Care Cancer Center. <i>Journal of Clinical Microbiology</i> , 2005, 43, 6120-6122.	1.8	99
248	In Vitro Pharmacodynamics of Amphotericin B, Itraconazole, and Voriconazole against <i>Aspergillus</i> , <i>Fusarium</i> , and <i>Scedosporium</i> spp. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 945-951.	1.4	111
249	Detection of Gliotoxin in Experimental and Human Aspergillosis. <i>Infection and Immunity</i> , 2005, 73, 635-637.	1.0	171
250	Pharmacodynamics of Polymyxin B against <i>Pseudomonas aeruginosa</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 3624-3630.	1.4	198
251	Murine Model of Invasive Aspergillosis. , 2005, 118, 129-142.		24
252	Genome-wide expression profiling reveals genes associated with amphotericin B and fluconazole resistance in experimentally induced antifungal resistant isolates of <i>Candida albicans</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2004, 54, 376-385.	1.3	100

#	ARTICLE	IF	CITATIONS
253	Pharmacodynamics of Caspofungin in a Murine Model of Invasive Pulmonary Aspergillosis: Evidence of Concentration-Dependent Activity. <i>Journal of Infectious Diseases</i> , 2004, 190, 1464-1471.	1.9	195
254	Invasive Aspergillosis in Patients with Hematologic Malignancies. <i>Pharmacotherapy</i> , 2003, 23, 1592-1610.	1.2	49
255	<i>Enterobacter cloacae</i> Ventriculitis Successfully Treated with Cefepime and Gentamicin: Case Report and Review of the Literature. <i>Pharmacotherapy</i> , 2003, 23, 537-542.	1.2	17
256	The Solubility Ceiling: A Rationale for Continuous Infusion Amphotericin B Therapy?. <i>Clinical Infectious Diseases</i> , 2003, 37, 871-872.	2.9	46
257	The echinocandin antifungals: an overview of the pharmacology, spectrum and clinical efficacy. <i>Expert Opinion on Investigational Drugs</i> , 2003, 12, 1313-1333.	1.9	130
258	Attenuation of Itraconazole Fungicidal Activity following Preexposure of <i>Aspergillus fumigatus</i> to Fluconazole. <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 47, 3592-3597.	1.4	18
259	Moxifloxacin. <i>Journal of Public Health Pharmacy</i> , 2003, 6, 1-26.	0.1	2
260	Antifungal Therapy. , 0, , 1423-1432.		0
261	Micafungin in the treatment of invasive candidiasis and invasive aspergillosis. <i>Infection and Drug Resistance</i> , 0, , 63.	1.1	4
262	Antifungal therapy. , 0, , 1344-1352.		0
263	Yeasts. , 0, , 343-365.		0